Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaboration0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Join our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessTom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo (2018). Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy. , 14
Tom van Hagen, Shahneen Sandhu, Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Meliessa Hennessy, Marcis Bajars, Christine Hicking, Sandra P. D’Angelo (2018). Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic merkel cell carcinoma (mMCC) progressed on chemotherapy. , 14
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2018
Authors
18
Datasets
0
Total Files
0
Language
en
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
